EHA 2016 | Pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Press brief by Klaus Metzeler, MD of the Ludwig-Maximilians University, Munich, Germany, at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up
An exciting era for CAR T-cell therapy
Utilizing MRD for AML in the clinical setting
Jorge Sierra et al.
AML treatment: what does the data say?
Adriano Venditti et al.
Biological mechanisms of AML: a 2019 update
Klaus Metzeler et al.
Molecular techniques for monitoring MRD in AML
More from Klaus Metzeler